|1.||Kojima, Tetsuhito: 8 articles (11/2015 - 05/2002)|
|2.||Lunde, Ida G: 4 articles (11/2015 - 01/2011)|
|3.||Christensen, Geir: 4 articles (11/2015 - 01/2011)|
|4.||Sjaastad, Ivar: 4 articles (11/2015 - 01/2011)|
|5.||Tønnessen, Theis: 4 articles (11/2015 - 01/2011)|
|6.||Echtermeyer, Frank: 4 articles (01/2015 - 01/2008)|
|7.||Ikesue, Masahiro: 3 articles (09/2015 - 05/2011)|
|8.||Uede, Toshimitsu: 3 articles (09/2015 - 05/2011)|
|9.||Morimoto, Junko: 3 articles (09/2015 - 05/2011)|
|10.||Hasic, Almira: 3 articles (05/2015 - 01/2011)|
03/01/2013 - "The present study was undertaken to analyze the functional role of syndecan 4 in endochondral ossification of mouse embryos and in adult fracture repair, which, like osteoarthritis, involves an inflammatory component. "
09/01/2009 - "Our data suggest that strategies aimed at the inhibition of syndecan-4 will be of great value for the treatment of cartilage damage in osteoarthritis."
09/01/2009 - "Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis."
10/01/2014 - "Previous studies support the important role of vascular endothelial growth factor (VEGF) and syndecan-4 in the pathogenesis of osteoarthritis (OA). "
03/01/2013 - "Syndecan 4, a heparan sulfate proteoglycan, has been associated with osteoarthritis. "
|3.||Wounds and Injuries (Trauma)
01/01/2001 - "In this study, we generated mice in which the syndecan-4 gene was disrupted by homologous recombination in embryonic stem cells to test the hypothesis that syndecan-4 contributes to wound repair. "
12/01/2012 - "Syndecan-4 null mice have a complex wound repair phenotype while their fibroblasts have reduced focal adhesions and matrix contraction abilities. "
10/18/2011 - "Like disruption of syndecan-4 or caveolin, gene disruption of RhoG in mice was found to retard closure of dermal wounds due to a migration defect of the fibroblasts and keratinocytes of RhoG null mice. "
02/01/2001 - "In the wound edge, syndecan-4 was predominantly expressed by epidermal basal layer cells. "
01/01/2001 - "Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4."
05/01/2011 - "The aim of the present study was to determine the clinical use of serum syndecan-4 concentration for diagnosis of heart failure. "
11/01/2015 - "Circulating shed syndecan-4 is increased in heart failure patients, however the pathophysiological and molecular consequences associated with syndecan-4 shedding remain poorly understood. "
08/01/2013 - "To detect serum level of syndecan-4 protein in patients with chronic congestive heart failure (CHF) and investigate its correlation with New York Heart Association (NYHA) class and echocardiographic parameters. "
08/01/2013 - "[Changes and clinical significance of serum level of syndecan-4 protein in patients with chronic congestive heart failure]."
05/01/2011 - "Serum syndecan-4 concentration shows promise as a novel diagnostic and prognostic biomarker for heart failure. "
|5.||Melanoma (Melanoma, Malignant)
01/01/2014 - "Here we show that Thy-1 supports β1 integrin- and syndecan-4 (Syn4)-mediated contractility-dependent mechanosignalling of melanoma cells. "
10/16/2009 - "Specifically, syndecan 1 and syndecan 4 expression correlated to Wnt5A expression and melanoma malignancy. "
06/01/2009 - "The reduction in syndecan-4 expression by utilizing specific siRNA discriminately increased melanoma cell motility and decreased their attachment on FN, demonstrating a regulatory role of syndecan-4 on these cell functions. "
12/01/2006 - "Genomic studies repeatedly revealed several novel melanoma marker genes including those of the transcription factor NOTCH2, WNT5A, proliferation-associated genes TOPO2A and CDC2, membrane receptors FGFR and EphA3, adhesion molecules N-cadherin, beta3 integrin and syndecan-4, and the cell surface antigens CD59/protectin and MIA. "
|2.||Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)
|3.||Syndecan-1 (Syndecan 1)
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||Toll-Like Receptors (Toll-Like Receptor)
|10.||Integrin beta3 (GPIIIa)